Yeah its easy to take shots at the fella.
But he was at the helm when the pivot to DMD happened. And was also at the helm for the studies that have opened the the pathway to potential platform drug status for ATL1102. So basically all the foundation for where we are now.
The timing of the change of leadership looks good to take the company over the next hurdles.
For General Information, page-2801
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.63M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 77428 | 8.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.6¢ | 76500 | 1 |
View Market Depth
| Last trade - 07.00am 21/06/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable